Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Dasatinib Bms354825

Research Leaders

12 sponsors active, led by Novartis

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 5 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

4Total
Phase 1 (1)
Phase 1/2 (1)
Phase 2 (2)

Trial Status

Completed4
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (5)

Showing 5 of 5 trials
NCT07362225Recruiting

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

NCT00255346Phase 2Completed

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

NCT00136409Phase 2Completed

A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)

NCT00088231Phase 1/2Completed

PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP

NCT00506402Phase 1Completed

A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies

Showing all 5 trials

Research Network

Common Treatments

  • Dasatinib Bms3548251
  • Mkc11
  • Ptk 787 Vatalanib1
  • Imatinib Mesylate Gleevec1
  • Imatinib Mesylate1

Active Sponsors

  • Novartis2
  • M.D. Anderson Cancer Center2
  • Karyopharm Therapeutics Inc1
  • Dana-Farber Cancer Institute1
  • Massachusetts General Hospital1

Top Investigators

Related Conditions

  • Myelofibrosis3
  • Polycythemia Vera2
  • Hematological Malignancies1
  • Hypereosinophilic Syndrome1
  • Accelerated Phase Myeloproliferative Neoplasm1

Activity Timeline